Aura Biosciences (AURA) 10-Q2024 Q3 Quarterly report

Filed: 12 Nov 24, 4:15pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: acetonide, adjuvant, anterior, ascending, cessation, cetrelimab, chamber, Conor, copy, cutoff, cystoscopy, de, disc, durability, East, effector, Elisabet, entirety, epithelium, Exhibit, exhibited, Finland, focal, gemcitabine, herewith, highlighting, Importantly, infiltration, Jill, Johnson, Kilroy, language, Lisbon, los, lump, Mark, Middle, mild, mitomycin, monotherapy, nonforfeitable, overturn, pain, parallel, pathology, pigment, Plavsic, poor, Portugal, President, presidential, Reconciliation, repeat, resection, Retina, retinal, Secretary, sequelae, shrinkage, staining, steroid, sum, tamoxifen, text, tissue, transurethral, triamcinolone, TURBT, undergone, untreated, urothelial, vast

Removed: Bio, disk, intravitreal, MA, Sesen, unresponsive

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

AURA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Aura Biosciences, Inc. (the “Company”) for the period ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned certifies, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of her knowledge:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


		Aura Biosciences, Inc.

Date:	November 12, 2024	By:	/s/ Elisabet de los Pinos
			Elisabet de los Pinos
			President and Chief Executive Officer
			(Principal Executive Officer)

Date:	November 12, 2024	By:	/s/ Amy Elazzouzi
			Amy Elazzouzi
			Vice President, Finance
			(Interim Principal Financial Officer and Interim Principal Accounting Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.